Home > Boards > US OTC > Biotechs >

NorthWest Biotherapeutics Inc. (NWBO)

Add NWBO Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, Barunuuk, Astavakra, sentiment_stocks, Know-Fear, HappyLibrarian
Search This Board: 
Last Post: 3/22/2018 1:33:55 PM - Followers: 580 - Board type: Free - Posts Today: 106

 Stylized Dendritic Cell featured on NWBO board since 2015

Ad from GoBoldly PhRMA Ad Campaign - 2017

"The UCLA Brain Tumor Program continues to shine as a beacon of hope, carrying a record of
patients with brain tumors living longer than patients treated at any other hospital.  
Our personalized brain cancer vaccine, DCVax, is the first of its kind and is currently in
Phase III clinical trials in 46 centers throughout America.  
It is on the road to FDA approval as well as clinical trials throughout Europe.  
Using this vaccine, we are harnessing the patient's immune system, genetics, pathology, brain mapping
and a wide database of bioinformatics to optimize outcomes."

- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA


"Clinical and immunopathological effects following Image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers" - Abstract #2499 - AACR (American Association for Cancer Research)
"Proffered Paper:  Prolonged Survival for Patients with Recurrent Glioblastoma Multiforme who are Treated with Tumor Lysate-Pulsed Autologous Dendritic Cells" - presented at ITOC-Conference, Munich, Germany - March 26, 2015, 14:40 - Marnix Bosch, Chief Technical Officer, NW Bio (note, abstract linked here is from Science Direct)

NWBO Board of Directors
Cofer Black, Independent Director
Alton L. Boynton, Chief Scientific Officer, Secretary and Director
Robert Farmer, Independent Director
Jerry Jasinowski, Independent Director
Navid Malik, Independent Director
Linda F. Powers, Chairman of the Board, President, CEO and CFO

Corporate Profile

NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.  NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.

Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer.  This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.

Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.  

 They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind) 
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz

Company Contact Info
Investor Relations:
Les Goldman  (Company)     (202) 841-7909
Michael Meehan (Media)      (202) 262-9081
Jane Searle (Media)             (212) 710-9685 or
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)

Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814  (240) 497-9024

DCVAX Survival Stories
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
NWBO GBM Brain Cancer Suvivial Story of Brad Silver
NWBO, GBM Brain Cancer Survival Story of Mike Gregoire
UCLA - Real Stories Using DCVax

Designations & Awards
German Hospital Exemption (referred to as HE) Information for DCVax-L® - FIRST TIME EVER

DCVax-L Hospital Exemption Program Now Under Way in Germany (NWBO, PR Newswire, October 14, 2014)
Two German Approvals:  "Hospital Exemption" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement (NWBO, March 10 2104)
Analysis:  NWBO DCVax-L German Approval Under Hospital Exemption Early Access Program (Smith on Stocks, Nasdaq, March 11, 2014)
Exclusive - Germany OKs Northwest Bio Brain Cancer Drug, Shares Soar (Ransdell Pierson, Reuters, March 10, 2014)

Fails-to-Deliver Data with the SEC
Data downloads

FINRA-Reg SHO Daily Files
Reported short sale trade data

FDA Endpoints & Approval Information
House committee approves bill to speed new drugs to market - May 21, 2015 (Toni Clarke, Reuters)
FDA could approve drugs fro new uses on less data:  draft law - April 29, 2015 (Toni Clarke, Reuters)
Richard Pazdur says FDA racing approvals due to unprecedented efficacy - April 15, 2015 (BioCentury TV)

United Kingdom Awards DC-Vax-L® as Promising Innovative Medicine (PIM) - FIRST TIME EVER
First UK "Promisting Innovative Medicine" Designation Awarded (Department of Health and George Freeman MP, Gov.UK, September 16, 2014)
NWBO's Cancer Vaccine is the First Drug to be Designated by UK Authorities as a "Promising Innovative Medicine" (PIM) - (NWBO, September 16, 2014)

Linda Powers Interview 5-15-12

Important or Helpful Links
NWBO Stock Quote & Information
NWBO SEC Filings
NWBO Twitter
NWBO Facebook
NWBO Yahoo Message Board

Upcoming Healthcare Conferences

Institutional Investments
Nearing "the finish line" on cancer vaccine trial, Maryland firm raises $40 million - April 3, 2015 (J.D. Harrison)
Northwest Biotherapeutics:  The $40 Million Woodford Financing is A Major Positive - April 3, 2105 (Smith on Stocks - Larry Smith)

Linda Liau - Principal Investigator for DCVax-L P3 Trial
12/19/16 Email to shareholder

NWBO Analysis
Northwest Biotherapeutics:  FDA Panel Recommendation to Approve Amgen's Cancer Vaccine is Hugely Significant In Regard to Possible Approval of DCVax-L and DCVax-Direct - May 1, 2015 (Smith on Stocks - Larry Smith)

Northwest Biotherapeutics:  Promising New Data Was Just Presented on DCVax-L in Recurrent Glioblastoma Mulitforme - March 27, 2015 (Smith on Stocks - Larry Smith)
Northwest Biotherapeutics:  How Much Will it Cost to Manufacture DcVax-L - March 5, 2015 (Smith on Stocks - Larry Smith)
The Potentially Key Role of Northwest Biotherapeutics in the Emerging Immuno-Oncology - February 3, 2105 (Smith on Stocks - Larry Smith)
Notes from Linda Powers Presentation in San Francisco - January 12, 2015 (Smith on Stocks - Larry Smith)
Current Investment Recommendations for Stocks Covered by SmithOnStocks; A Yearend Review - December 19, 2014 (Smith on Stocks - Larry Smith)
NWBO discussed at great length.
NWBO:  Putting Recent Clinical Data on DCVax Direct in Perspective - November 28, 2014 (Smith on Stocks - Larry Smith)
DCVax-L:  A Reimbursement Perspective - November 22, 2014 (Seeking Alpha - Ryan Pawell)
DCVax-Direct Validation and Updated DCVax-L Ph III Modeling - November 6, 2014 (Seeking Alpha - Steven Giardino [Pyrr])
Now is the Time for Northwest Biotherapeutics - October 29, 2014 (Seeking Alpha - Steven Giardino (Pyrr)
U.K. May Grant Early Patient Access for DCVax-L Priot to Formal Approval  - September 18, 2014 (Seeking Alpha - Larry Smith [Smith on Stocks])
Exciting News on Potential for Early Patient Access for DCVax-L in the UK - September 17, 2014 
(Larry Smith, Smith on Stocks)
The Data Monitoring Commitee Addresses the Status of the DCVax-L Trial - August 13, 2014 (Seeking Alpha - Larry Smith [Smith on Stocks])

NWBO Press Releases 
NWBO Yahoo Headlines

NWBO Older News
NWBO Receives Approval for US Patent for Cost Saving Automation of High-Concentration DCVax Manufacturing - Already cleared by FDA for use in Clnical Trials
- December 4, 2009

UK News Coverage
Cancer Treatments - Supplement in United Kingdom Times April 6, 2015
NW Bio Announces $40 Million Financing - Further Equity by Woodford Funds April 2, 2015
Woodford's new biotech could be the next Amgen November 26, 2014 (Gavin Lumsden, Citywire Money)
Neil Woodford invests £16m in brain cancer vaccine company November 19, 2014 (Ashley Armstrong, The Telegraph)

NWBO - Short Seller Rebuttals and Information
Washington Post - Pulitzer Prize Winning Steven Pearlstein addresses NWBO and Short Selling
Citizens for Responsibility and Ethics in Washington (CREW) Requests SEC Investigate Manipulation of Drug Company Stock Price to Benefit Short Sellers
My Dialogue with Adam Feuerstein on Northwest Biotherapeutics - September 25, 2014 (Larry Smith, Smith on Stocks)
Jim Cramer Explains How the Stock Market is Manipulated - sounds a bit like some of the techniques used here.

Patent Information
Espacenet Patent information for NWBO
Patentdocs - Patent applications for NWBO
JUSTIA Patents
NWBO Receives U.S. Patent on Broad Processes for Producing More Potent Dendritic Cells - March 18, 2013 
NWBO's Patent Portfolio is Further Expanded with Manufacturing Automation Patent - September 10, 2013
NWBO Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax Manufacturing - December 4, 2009
NWBO - Wikiinvest Intellectual Property - from the 10-K filed April 15, 2008

Patient Info
Prospective patients may contact NW Bio at
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer

"Developments in Neurosurgery for brain tumors" - by UK/Europe Primary Investigator - King's College Hospital (UK) Professor Keyoumars Ashkan (see minute 8:18) - Published 7-18-17 by The Brain Tumour Charity
"Advances in Glioblastoma Treatment" - by Colorado Primary Investigator - Boulder Neurosurgical Associates - Michael Pearlman, M.D. (see minute 19:10) - Published November 22, 2015

Orphan Drug Report 2014  (EvaluatePharma, October 2014 - see page 14 ) 

Research Posters
AARC April 2015 - Prolonged Survival in Patients with Recurrent Glioblastoma Multiforme Who are Treated with Tumor Lysate-Pulsed Autologous Dendritic Cells
AARC April 2015 - Clinical and Immunopathological Effects Following Image-guided Intratumoral Injection of Activated, Autologous Dendritic Cells in Patients with Advanced Solid Cancers
SITC 2014 - Direct
ASCO 2014 - Direct

Scientific Advisory Board
Dr. Mac Cheever - Fred Hutchison Cancer Research Center (FHCRC), Professor of Medicine and Director of NCI-funded Cancer Immunotherapy Trials Network (CITN)
Dr. Alfredo Quinoones-Hinojosa - William J. and CharlesH. Mayo Professor, Chair of Neurologic Sugery, Mayo Clinic in Jacksonville, FL, 
Dr. Jerome Galon - French Biologist, Ph.D. in Immunology, Cordeliers Research Center, Director of the INSERM Laboratory Integrative Cancer Immunology
Dr. Samir N. Khleif - Director of the GRU Cancer Center, Augusta, GA
Dr. John Smyth - Professor Emeritus Medical Oncology and Honorary Assistant Principal Cancer Research Development
PR Announcement: - June 13, 2016

Sawston Location
US Biotechnology Company Doses Upon Space in Cambridge - link is to i-hub post with story.  Actual story requires sign up.

SEC Reports
Form 10-Q - for fiscal 3rd Quarter ending September 30, 2017
Form 10-Q - for fiscal 2nd Quarter ending June 30, 2017
Form 10-Q - for fiscal 1st Quarter ending March 31, 2017
Form 10-K - for fiscal year ending December 31, 2016
Form 10-Q - For fiscal 3rd Quarter ending September 30, 2016
Form 10-Q - for Fiscal 2nd Quarter ending June 30, 2016
Form 10-Q- for Fiscal 1st Quarter ending March 31, 2016
Form 10-K - For fiscal year ended December 31, 2015

Short Report
OTC - FINRA - Equity Short Interest

Stock Quote & Summary
As of October 24, 2017 - approximate and subject to verification 

Common Shares Outstanding:   310,194,613 
Options Outstanding:                    11,343,117
Convertible Notes:                      121,689,276
Share purchase warrants:              TBD

Total Fully Diluted Shares:       443,227,006

Inside Ownership of NWBO Common Stock held (12-01-2016) - DOES NOT include currently exercisable warrants or options - which cannot be voted with: 
 0.2% Security Holders - Employees/Directors                                  399,158  (Boynton, Bosch, Goldman, Farmer, Jasinowski)
0.84% Security Holder - Director                                                    1,285,714  (additionally on 12-27-16 by Jerry Jasinowski)
1.02%  Security Holder  - Linda Powers                                         1,572,500
0.52%    Security Holder - Toucan Capital Fund                                804,145
1.4%    Security Holder- Toucan Partners, LLC                             2,211,784
8.9%  Security Holder – Cognate BioServices (12-1-16)):            13,684,294
16.17%  Security Holder - Woodford Investment Management    24,815,028
2.6%  Security Holder – Dennis Mehiel:                                         4,125,949 (under 5%, not listed on 11-6-15 Proxy)

Total (12-01-2016):                                                                       48,898,572

Total Number of Common Stock Shares:  153,421,687

Highest Share Price after Last Reverse Split:  $12.55 (July 2015)
52-Week High -
52-Week Low -  .14¢

Transfer Agent 
Computershare Trust Company, N.A.

P.O. Box 30170, College Station, Texas  77842
Monday through Friday. Call (866) 282-9695.

UCLA Department of Neurology
UCLA Chair of Neurosurgery Linda Liau, PhD - Welcome Letter
DCVax in 4th paragraph - "on the road to FDA approval"

A Personal Quest to Cure Brain Cancer - (Into The Brain and Beyond by UCLA Neurosurgery)

UCLA Trials relating to Dendritic Cells
Vaccine Therapy in Treating Patients with Malignant Glioma NCT00612001
Vaccine Therapy in Treating Young Patients Who are Undergoing Surgery for Malignant Glioma NCT00107185
Vaccine Therapy in Treating Patients with Malignant Glioma NCT00068510
Vaccine Therapy in Treating Patients with Stage IV or Relapsed Malignant Melanoma NCT00005617
Autologous Dendritic Cells in Treating Patients with Metastatic Kidney Cancer NCT01826877
Vaccine Therapy in Treating Patients who are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-SMall Cell Lung Cancer NCT00098917
Vaccine for Patients with Newly Diagnosed or Recurrent Low-Grade Glioma NCT01635283
Dendritic Cell Vaccine for Ptients with Brain Tumors NCT01204684
Vaccine Therapy in Treating Patients with Unresected Stage III or Stage IV Melanoma NCT00107159
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients with Locally Advanced or Mestastatic Malignancies NCT02070406

Upcoming Events
Immuno-Oncology Frontiers World - Linda Powers, CEO - "Achieving both precision targeting and broad spectrum immunotherapy" - Tuesday, January 23, 2018, 10:15 to 10:30 a.m. EST - Miami, Florida

Recent Past Presentations
Cancer Vaccines and Neoantigens - Marnix L. Bosch, CTO - August 31, 2017 - Slides
Update on Clinical Programs - Marnix L. Bosch, CTO - ASCO 2017 - June 5, 2017

Robert Prins, MD - The Future of Vaccine Treatment in Brain Cancer - March 28, 2016, Seattle Science Foundation
    Partial Transcript of Prins' Presentation
Linda Liau, MD - Immunotherapies for GBM:  Tumor Vaccines by Linda Liau, M.D., Ph.D., M.B.A. - December 15, 2016, Seattle Science Foundation

ASCO 2015 - Overview of DCVax Direct Phase 1 Trial - May 30, 2015 - Webcast by Marnix L. Bosch, MBA, PhD, CTO, NWBO (YouTube)
   Slides presented in ASCO presentation to accompany Video
  Partial Transcription of Dr. Bosch Video
NWBO Virtual Investor Conference - May 7, 2015 - Webcast by Linda Powers, CEO, NWBO (sign-up required)
NWBO Presentation at ITOC2 Conference - March 26, 2015 - Webcast by Marnix L. Bosch, MBA, PhD, CTO, NWBO (YouTube)
NWBO Presentation at BIO CEO & Investor Conference - February 9, 2015 - Webcast by Linda Powers
NWBO Presentation at Phacilitate Immunotherapy World 2015 - January 26, 2015 - Webcast by Linda Powers (YouTube)
Transcript of Biotech Showcase 2015 - from January 12, 2015 - provided by sentiment_stocks
NWBO- 25th Annual Oppenheimer Healthcare Conference - December 10, 2014 - accompanying Slide Show
Transcript of 25th Annual Oppenheimer Healthcare Conference - provided by RK (Includes Q&A at the end)
NWBO Linda Powers Presents at SMi 3rd Cancer Vaccines Conference 2014 - Linda announces England's 1st PIM (Promising Innovative Medicine) Designation and Recent Progress to Date and offers an excellent explanation of how DCVax works

NWBO Company Website
Wiki page for NWBO
Informative Investor Website
Immunology Acronyms

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NWBO News: Current Report Filing (8-k) 03/20/2018 05:11:43 PM
NWBO News: Current Report Filing (8-k) 03/15/2018 05:21:44 PM
NWBO News: Current Report Filing (8-k) 03/07/2018 04:06:26 PM
NWBO News: StereoVision (SVSN) $420 million in Sales from $1,000 Acre Hemp Farm Lease 03/06/2018 06:47:36 AM
NWBO News: Current Report Filing (8-k) 03/02/2018 05:27:04 PM
PlusOneCoin Top Posts
#162973   Perhaps The Publication Is Necessary. flipper44 03/20/18 11:55:19 AM
#162835   biosectinvestor, doingmybest 03/19/18 10:00:16 AM
#162796   doingmybest, That is 100% correct and a perusal through Doc logic 03/18/18 10:45:46 PM
#161659  Sticky Note Speaking of long cancer vaccine trials, here is flipper44 03/08/18 08:47:31 PM
#161364  Sticky Note To me, the publication is now officially late. flipper44 03/07/18 01:28:36 PM
#157234  Sticky Note CALENDAR UPDATE (February 7, 2018) flipper44 02/07/18 01:53:00 PM
#140299  Sticky Note PR About the Lawsuits TC_Trader 10/25/17 09:49:10 AM
#44577  Sticky Note Ummm, have any of you people ever read IH Admin [Shelly] 11/08/15 07:37:32 PM
#39690  Sticky Note The topic to be discussed here is NWBO. IH Dan (Retired) 08/31/15 12:21:09 PM
#161613   I am sure they have thought of the manibiotech 03/08/18 04:47:20 PM
#161612   What is the purpose of blinded publication...we already sentiment_stocks 03/08/18 04:42:25 PM
#161611   So it may be probable that we see Ultraz2 03/08/18 04:38:18 PM
#161610   I disagree, I don't believe it's priced in. nwbohica 03/08/18 04:35:42 PM
#161609   I thought there was a 6 month wait Ultraz2 03/08/18 04:33:22 PM
#161608   That’s exactly what I said . I wrote manibiotech 03/08/18 04:32:58 PM
#161607   What is the purpose of blinded publication...we already Ultraz2 03/08/18 04:31:13 PM
#161606   How can you be sure? I think the nwbohica 03/08/18 04:30:14 PM
#161605   Aren’t we expecting a share raise before all Ultraz2 03/08/18 04:28:38 PM
#161604   Even further when the increase takes placed though martyDg 03/08/18 04:27:05 PM
#161603   Presumably, but LP expects it to take the flipper44 03/08/18 04:26:40 PM
#161602   the most important "something" released .... patients are evanstony 03/08/18 04:26:26 PM
#161601   Dilution is already priced in IMhO manibiotech 03/08/18 04:25:34 PM
#161600   Anybody here thinking to unload their shares before martyDg 03/08/18 04:23:46 PM
#161599   Price held up pretty good considering 8-k. nwbohica 03/08/18 04:23:07 PM
#161598   Presumably the spring refresh would become easier each Hbpainter 03/08/18 04:20:14 PM
#161597   I agree...I just lightened holdings by 10k...don’t like Ultraz2 03/08/18 04:09:05 PM
#161596   Thanks point worth noting:-) pgsd 03/08/18 03:52:59 PM
#161594   ASCO 2015, I anxiously await. LessIsMore 03/08/18 03:47:01 PM
#161593   If topline were to be released around ASCO, flipper44 03/08/18 03:44:07 PM
#161592   Back to 20's, are we crazy thinking Linda Milner1 03/08/18 03:37:06 PM
#161591   I hope you are right. Of all the pgsd 03/08/18 03:35:25 PM
#161590   Hmmm...will be behind 8 ball soon! Phase 3 randomized, Ultraz2 03/08/18 03:29:58 PM
#161589   It as unbelievable that she would choose such manibiotech 03/08/18 03:27:44 PM
#161588   I think it's not Linda's call. I flipper44 03/08/18 03:19:55 PM
#161587   hankmanhub, I thought I made myself clear in my Doc logic 03/08/18 03:07:22 PM
#161586   Well Linda has potentially forewarned us of further pgsd 03/08/18 03:07:10 PM
#161585   I don't think she mentioned DMC once at flipper44 03/08/18 03:04:41 PM
#161584   I don't recall him "feeling bad." I flipper44 03/08/18 03:02:59 PM
#161583   The only positive that came from such a beachhyena 03/08/18 02:58:02 PM
#161582   I didn't mean overlooked over the years, I flipper44 03/08/18 02:57:53 PM
#161581   but, it would be a, uh, reasonable thought chinatown1980 03/08/18 02:55:32 PM
#161580   Absolutely why not? the whole conference is about marzan 03/08/18 02:55:21 PM
#161579   Good questions. I tend to think the flipper44 03/08/18 02:54:49 PM
#161578   Wasn't overlooked by me. Diamondjim61 03/08/18 02:52:30 PM
#161577   To accomodate the publications and the ripple effect flipper44 03/08/18 02:47:19 PM
#161576   Flipper44, thank you for this post. IYHO, will reg2015 03/08/18 02:44:11 PM
#161575   flip are you saying that the whole conference JTORENCE 03/08/18 02:37:26 PM
#161574   Come on, Flipper, share!!! It’s the only fair beartrap12 03/08/18 02:35:00 PM
#161573   I thought this portion from the ASM was flipper44 03/08/18 02:31:52 PM
#161572   Senti,I wish I had an answer, the data Hspooner 03/08/18 02:02:20 PM
#161571   Glad the warrant holders aren't selling now. Wouldn't nwbohica 03/08/18 01:58:19 PM
#161569   I wonder... CaptainOblivious 03/08/18 01:35:11 PM
#161567   Wonder no longer. He's very purposeful in sentiment_stocks 03/08/18 01:33:22 PM
#161566   I was reading AFs latest article about DCVax photonic5 03/08/18 01:25:45 PM
#161565   Do you think that 59 weeks from the sentiment_stocks 03/08/18 01:23:00 PM
#161564   Linda Powers explained at the ASM they can't flipper44 03/08/18 01:22:28 PM
#161563   Because that also addressed expectations that the data kabunushi 03/08/18 01:16:27 PM
#161562   Will you post this on IV aswell? Haven't Hbpainter 03/08/18 01:13:58 PM
#161560   I've also had a change with my impression flipper44 03/08/18 12:48:35 PM